CompletedPhase 2NCT01908777
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Studying T-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Steven Horowitz, MDMemorial Sloan Kettering Cancer Center
- Intervention
- High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin(other)
- Enrollment
- 47 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2013 – 2025
Study locations (10)
- Moffitt Cancer Center, Tampa, Florida, United States
- Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
- Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
- Memorial Sloan Kettering Westchester, Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Weill Cornell Medical Center, New York, New York, United States
- Memorial Sloan Kettering Nassau, Uniondale, New York, United States
- Fred Hutchinson Cancer Research Center (Data Collection Only), Seattle, Washington, United States
- University of Washington (Data Collection Only), Seattle, Washington, United States
Collaborators
University of Washington · Weill Medical College of Cornell University · H. Lee Moffitt Cancer Center and Research Institute
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01908777 on ClinicalTrials.govOther trials for T-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05989204TmCD19-IL18 in CD19+ CancersUniversity of Pennsylvania
- ACTIVE NOT RECRUITINGPHASE1NCT05377827Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic MalignanciesWashington University School of Medicine
- RECRUITINGPHASE1, PHASE2NCT04440436Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) PatientsBeijing Immunochina Medical Science & Technology Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE1NCT03434769AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin LymphomaBenjamin Tomlinson
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02690545Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHLUNC Lineberger Comprehensive Cancer Center